My preliminary thoughts on the latest update:
- Very stong expansion in Gross Margin to 65.6% from just 56.6% only 6 months ago. The higher the gross margin, the more capital a company retains, which it can then use to help support sustainable growth.
- Over the last 6 months, JAN has used $3.0M of the additional $4.7M of Gross Profit in increased Operating Expenses. Operating Expenses are the engine room of innovation, sales, marketing and (non-capitalised) research and development. This gives me confidence about continued stong growth for JAN.
- Because of this increased investment in growth, EBITDA and profit growth has been delayed. IMO both profit measures will be higher and grow faster within the next 2 years than if JAN had prioritised early profit growth by not investing for growth. Shareholders should benefit from that.
- Forums
- ASX - By Stock
- Ann: JAN Preliminary 1H22 Results Update
My preliminary thoughts on the latest update:Very stong...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add JAN (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $46.77M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 18.0¢ | $5.236K | 29.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12033 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 800 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12033 | 0.180 |
1 | 35000 | 0.175 |
6 | 98194 | 0.170 |
1 | 6000 | 0.165 |
3 | 54000 | 0.160 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 800 | 1 |
0.190 | 10390 | 3 |
0.195 | 5000 | 1 |
0.200 | 12400 | 3 |
0.205 | 7650 | 1 |
Last trade - 10.16am 12/11/2024 (20 minute delay) ? |
Featured News
JAN (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online